- Home
- ZTR vs FDMT Comparison
ZTR vs FDMT Comparison
Compare ZTR & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZTR
- FDMT
- Stock Information
- Founded
- ZTR 1988
- FDMT 2013
- Country
- ZTR Australia
- FDMT United States
- Employees
- ZTR N/A
- FDMT N/A
- Industry
- ZTR Investment Managers
- FDMT Biotechnology: Pharmaceutical Preparations
- Sector
- ZTR Finance
- FDMT Health Care
- Exchange
- ZTR Nasdaq
- FDMT Nasdaq
- Market Cap
- ZTR 368.5M
- FDMT 420.7M
- IPO Year
- ZTR N/A
- FDMT 2020
- Fundamental
- Price
- ZTR $5.81
- FDMT $5.97
- Analyst Decision
- ZTR
- FDMT Buy
- Analyst Count
- ZTR 0
- FDMT 11
- Target Price
- ZTR N/A
- FDMT $42.80
- AVG Volume (30 Days)
- ZTR 219.4K
- FDMT 732.6K
- Earning Date
- ZTR 01-01-0001
- FDMT 11-13-2024
- Dividend Yield
- ZTR 12.09%
- FDMT N/A
- EPS Growth
- ZTR N/A
- FDMT N/A
- EPS
- ZTR N/A
- FDMT N/A
- Revenue
- ZTR N/A
- FDMT $17,000.00
- Revenue This Year
- ZTR N/A
- FDMT N/A
- Revenue Next Year
- ZTR N/A
- FDMT $87.55
- P/E Ratio
- ZTR N/A
- FDMT N/A
- Revenue Growth
- ZTR N/A
- FDMT N/A
- 52 Week Low
- ZTR $4.50
- FDMT $5.77
- 52 Week High
- ZTR $6.60
- FDMT $36.25
- Technical
- Relative Strength Index (RSI)
- ZTR 28.95
- FDMT 27.40
- Support Level
- ZTR $6.01
- FDMT $6.42
- Resistance Level
- ZTR $6.26
- FDMT $7.58
- Average True Range (ATR)
- ZTR 0.07
- FDMT 0.44
- MACD
- ZTR -0.04
- FDMT -0.07
- Stochastic Oscillator
- ZTR 0.00
- FDMT 9.24
About ZTR Virtus Total Return Fund Inc.
Virtus Total Return Fund Inc is a closed-end, diversified management investment company. Its investment objective is capital appreciation, with current income as a secondary objective through a balance of equity and fixed income investments. It invests in operators of infrastructure in the communications, utility, energy, and transportation industries.
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.